Digital pathology (DP) is transitioning from an adjunct technology to an enterprise diagnostic platform in the United States. Despite accelerating clinical adoption, many laboratories face persistent barriers, including high capital and operating costs, workflow disruption, interoperability challenges, and a complex regulatory and reimbursement environment.